Evaluation of brain natriuretic peptide in patients with type 2 diabetes

The purpose of the current study was to use brain natriuretic peptide (BNP) as a biomarker to find a novel approach for identifying and forecasting atrial and ventricular pre-systole (PVS), a significant illness. Following a monthly check-up for patients with type 2 diabetes, the study was carried out at Al-Sadr Hospital clinics and private laboratories in the Najaf Governorate, Iraq, from September 1, 2024, to February 1, 2025. There were 90 patients in all, 60 of whom had PVS and 30 healthy controls. Age, type of PVS (atrial and ventricular), diagnosis (treated or newly diagnosed), length of disease, hypertension (hypertension or normotension), and body mass index (BMI) group were used to categorize the patients into subgroups. In comparison to the control group, the current results demonstrated a substantial rise (P<0.05) in BNP. There was a significant difference (P<0.05) between the male and female patient groups. The current findings also showed that the prevalence of ventricular arrhythmia was substantially (P<0.05) greater in older individuals (60–69 years) than in those who already had ventricular arrhythmia. The current findings showed a significant (P<0.05) difference in patients with newly identified ventricles. Additionally, the current study showed that the biomarker increased in the hypertension group in a very significant (P<0.05) way. The patient groups' sickness durations (from 1 week to 1 month) were substantially (P<0.05) longer than those of those aged 1–5 and >5 years. The prevalence of obesity was substantially greater (P<0.05) in the obese patient group compared to the overweight and normal weight groups based on BMI.